These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 142820)

  • 1. Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease.
    Schwarcz R; Bennett JP; Coyle JT
    J Neurochem; 1977 Apr; 28(4):867-9. PubMed ID: 142820
    [No Abstract]   [Full Text] [Related]  

  • 2. Huntington's disease and its animal model: alterations in kainic acid binding.
    Beaumont K; Maurin Y; Reisine TD; Fields JZ; Spokes E; Bird ED; Yamamura HI
    Life Sci; 1979 Feb; 24(9):809-16. PubMed ID: 156298
    [No Abstract]   [Full Text] [Related]  

  • 3. Striatal ganglioside levels in the rat following kainic acid lesions: comparison with Huntington's disease.
    Higatsberger MR; Sperk G; Bernheimer H; Shannak KS; Hornykiewicz O
    Exp Brain Res; 1981; 44(1):93-6. PubMed ID: 6456150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Activity of dopaminergic neurons of the substantia nigra following lesions of the neostriatum by kainic acid].
    Doudet D; Gross C; Bioulac B
    C R Seances Soc Biol Fil; 1984; 178(3):298-306. PubMed ID: 6238656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kainic acid binding in human caudate nucleus: effect of Huntington's disease.
    Henke H
    Neurosci Lett; 1979 Oct; 14(2-3):247-51. PubMed ID: 161000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Displacement of specific serotonin and lysergic acid diethylamide binding by Ergalgin, a new antiserotonin drug.
    Oelszner W
    Acta Biol Med Ger; 1980; 39(8-9):897-901. PubMed ID: 7282219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body weight, feeding, and drinking behaviors in rats with kainic acid-induced lesions of striatal neurons--with a note on body weight symptomatology in Huntington's disease.
    Sanberg PR; Fibiger HC
    Exp Neurol; 1979 Dec; 66(3):444-66. PubMed ID: 158536
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate.
    Whitaker PM; Seeman P
    Proc Natl Acad Sci U S A; 1978 Dec; 75(12):5783-7. PubMed ID: 32537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kainic acid: insights from a neurotoxin into the pathophysiology of Huntington's disease.
    Coyle JT; Ferkany JW; Zaczek R
    Neurobehav Toxicol Teratol; 1983; 5(6):617-24. PubMed ID: 6142425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased receptor-binding sites for kainic acid in brains of patients with Huntington's disease.
    London ED; Yamamura HI; Bird ED; Coyle JT
    Biol Psychiatry; 1981 Feb; 16(2):155-62. PubMed ID: 6452910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intrastriatal kainic acid in rats.
    Arregui A; Emson PC; Spokes EG
    Eur J Pharmacol; 1978 Nov; 52(1):121-4. PubMed ID: 214307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serotonin and D-lysergic acid diethylamide receptors in the mammalian brain].
    Vlasova TI; Kirzon MV
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1981; (5):5-16. PubMed ID: 6264979
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.
    Peroutka SJ; Snyder SH
    Mol Pharmacol; 1979 Nov; 16(3):687-99. PubMed ID: 530254
    [No Abstract]   [Full Text] [Related]  

  • 14. Huntington's chorea. Changes in neurotransmitter receptors in the brain.
    Enna SJ; Bird ED; Bennett JP; Bylund DB; Yamamura HI; Iversen LL; Snyder SH
    N Engl J Med; 1976 Jun; 294(24):1305-9. PubMed ID: 4733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, neuropathologic and pharmacologic aspects of Huntington's disease: correlates with a new animal model.
    Coyle JT; Schwarcz R; Bennett JP; Campochiaro P
    Prog Neuropsychopharmacol; 1977; 1(1-2):13-30. PubMed ID: 214805
    [No Abstract]   [Full Text] [Related]  

  • 16. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
    Dure LS; Young AB; Penney JB
    Ann Neurol; 1991 Dec; 30(6):785-93. PubMed ID: 1665055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antidepressant drugs on cerebral serotonin receptor mechanisms.
    Ogren SO; Fuxe K; Agnati LF; Celani MF
    Acta Pharmacol Toxicol (Copenh); 1985; 56 Suppl 1():105-27. PubMed ID: 3984752
    [No Abstract]   [Full Text] [Related]  

  • 18. A possible role of serotonin receptors in antidepressant drug action.
    Snyder SH; Peroutka SJ
    Pharmacopsychiatria; 1982 Jul; 15(4):131-4. PubMed ID: 7146092
    [No Abstract]   [Full Text] [Related]  

  • 19. [3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's diseased basal ganglia.
    Schoemaker H; Morelli M; Deshmukh P; Yamamura HI
    Brain Res; 1982 Sep; 248(2):396-401. PubMed ID: 6291702
    [No Abstract]   [Full Text] [Related]  

  • 20. 125I-LSD autoradiography confirms the preferential localization of caudate-putamen S2 receptors to the caudal (peripallidal) region.
    Altar CA; Boyar WC; Marien MR
    Brain Res; 1986 Apr; 372(1):130-6. PubMed ID: 2423187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.